Actively Recruiting
Neo-Sequence 2：NCT Plus Anti-angiogenesis Therapy and Immunotherapy for LADGC
Led by Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Updated on 2024-04-17
67
Participants Needed
1
Research Sites
156 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The regimen of Albumin paclitaxel+SOX+BEV neoadjuvant therapy lasted for 6 cycles, during which PD-1 monoclonal antibody therapy was interspersed for 4 cycles for locally advanced diffuse gastric cancer.
CONDITIONS
Official Title
Neo-Sequence 2：NCT Plus Anti-angiogenesis Therapy and Immunotherapy for LADGC
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with locally advanced diffuse or mixed type gastric cancer by pathology and endoscopy
- Diagnosed with T3-4NanyM0 gastric cancer or gastroesophageal junction cancer based on CT, ultrasound, gastroscopy, and endoscopic ultrasound
- No prior anti-tumor treatment for gastric cancer
- Aged between 18 and 75 years old
- ECOG performance status score of 0 or 1
- Adequate liver and kidney function and blood counts: neutrophils >1.5G/L, hemoglobin >90g/L, platelets >100G/L; ALT and AST <2.5 times upper limit of normal; total bilirubin <1.5 times upper limit of normal; creatinine <1.0 times upper limit of normal
- Left ventricular ejection fraction greater than 60%
- Able to comply with long-term follow-up
- Provided signed informed consent
You will not qualify if you...
- Gastrointestinal obstruction or uncontrolled recurrent bleeding
- Inability to swallow pills
- Immunodeficiency or active autoimmune diseases, or use of immunomodulators, systemic steroids, or immunosuppressive drugs within the past two years
- Interstitial pneumonia
- Moderate to severe cirrhosis from any cause
- Uncontrolled hypertension, severe kidney disease, or significant cardiovascular or cerebrovascular diseases
- Active infections requiring systemic treatment
- Previous history of other tumors except cured skin cancer or cervical cancer in situ
- Internal medical diseases unsuitable for chemotherapy
- Pregnancy or lactation
- History of mental illness or poor compliance
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Cancer hospital，Chinese acadamy of medical sciences
Beijing, China
Actively Recruiting
Research Team
C
Chunxia Du, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here